Oxy-Gard
- Manufacturer
- Ecolab Inc.
- Effective date
- 2025-07-17
- Label type
- OTC ANIMAL DRUG LABEL
- Version
- 5
- Source
- full-release
- Hydrated at
- 2026-06-01 02:44:46
Label at a glance#
ProductOxy-Gard
Active ingredientHYDROGEN PEROXIDE, DODECYLBENZENESULFONIC ACID, LACTIC ACID
Label structure4 sections
Contacts and useful links#
Websitewww.ecolab.com
www.ecolab.com
www.ecolab.comLabel contents#
Full prescribing information#
SAFE HANDLING WARNING SECTION
WARNING
KEEP OUT OF REACH OF CHILDREN
FOR INDUSTRIAL USE ONLY
NOT FOR HUMAN USE
Causes eye irritation
Wash skin thoroughly after handling. Do not mix with bleach or other chlorinated products – will cause chlorine gas.
VETERINARY INDICATIONS SECTION
DIRECTIONS:
IMPORTANT: Do not further dilute with water or mix with any other teat dips. If product in dip cup becomes visibly dirty, discard contents and replenish with fresh product. Do not reuse or return any unused product to the original container.
Udder Prep: When using an udder wash step before milking, make sure to wash teats with appropriate udder wash solution using proper cleaning procedures. Teats should then be dried with single-service towels.
Directions for Teat Dipping
Pre-Milk Dipping: Before each cow is milked, and using fresh Oxy-Gard, dip each teat full-length into the teat dip cup. Wipe teats after dipping using single-service towels to avoid contamination of milk.
Post-Milk Dipping: Using fresh Oxy-Gard, dip each teat full-length into the teat dip cup. Do not wipe. Allow to air dry. Do not turn cows out in freezing weather until the product is completely dry.
Directions for Teat Spraying
Pre-Milk Spraying: Before each cow is milked, and using fresh Oxy-Gard, spray entire teat. Wipe teats after dipping using single-service towels to avoid contamination of milk.
Post-Milk Spraying: Using fresh Oxy-Gard, spray entire teat immediately after each milking. Do not wipe. Allow to air dry. Do not turn cows out in freezing weather until the product is completely dry.
Expanded Usage: When freshening cows, begin dipping teats twice daily for about 10 days before calving.
PRECAUTION: Oxy-Gard is not intended to cure or help the healing of chapped or irritated teats. As with any germicide, irritation or sensitization may occur in sensitive animals. In case of teat irritation or chapping, have the condition examined and, if necessary, treated by a veterinarian.
Consult your Ecolab representative for specific use instructions and recommended dispensing equipment.
OTHER SAFETY INFORMATION
Read other label for directions for use, first aid and precautionary statements
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/ attention.
READ SAFETY DATA SHEET (SDS) BEFORE USING THIS PRODUCT
EMERGENCY HEALTH INFORMATION: 1 800 328 0026. If located outside the United States and Canada, call collect 1 651 222 5352 (number is in the US).
Principal Display Panel / Representative Label
ECOLAB
Oxy-Gard™
Sanitizing Teat Dip
An aid in reducing the spread of organisms which may cause mastitis
ACTIVE INGREDIENTS:
Hydrogen Peroxide................................................... 0.5%
Lactic Acid................................................................... 1.7%
Dodecyl Benzene Sulfonic Acid............................ 0.5%
INERT INGREDIENTS:.......................................... 97.3%
(contains glycerin, sorbitol)
TOTAL:..................................................................... 100.0%
766581/5300/1016
18.9 L (5 US GAL)
6301973
CAUTION
VENTED CONTAINER.
OPEN OR VENT
WITH CARE.
Ecolab · 1 Ecolab Place · St Paul MN 55102 USA · tel: 1 800 392 3392
© 2016 Ecolab USA Inc. · All rights reserved
Made in U.S.A.
www.ecolab.com · 766585/5300/1016
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 993253 | benzenesulfonic acid 0.5 % / lactic acid 1.7 % / hydrogen peroxide 0.5 % Topical Solution | PSN | 5 |
| 993261 | Oxy Gard 0.5 % / 1.7 % / 0.5 % Topical Solution | PSN | 5 |
| 993261 | benzenesulfonic acid 5 MG/ML / hydrogen peroxide 5 MG/ML / lactic acid 17 MG/ML Topical Solution [Oxy Gard] | SBD | 5 |
| 993253 | benzenesulfonic acid 5 MG/ML / hydrogen peroxide 5 MG/ML / lactic acid 17 MG/ML Topical Solution | SCD | 5 |
| 993253 | benzenesulfonic acid 0.5 % / hydrogen peroxide 0.5 % / lactic acid 1.7 % Topical Solution | SY | 5 |
| 993261 | Oxy Gard (benzenesulfonic acid 0.5 % / hydrogen peroxide 0.5 % / lactic acid 1.7 % ) Topical Solution | SY | 5 |
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| LACTIC ACID, UNSPECIFIED FORM Pharmacologic Class Indexing | 1 | Indexing - Pharmacologic Class | 20220121 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| f52be47f-7aa7-46c0-b1fa-50c18dd50206 | Product name | 1 | 20201029 |
| 444b3e50-f226-46ef-bfca-2e7035d140cd | Product name | 1 | 20190611 |
| 7cda52fc-125f-421c-8fea-bc1974370c49 | Product name | 2 | 20180703 |
| 5eb9f24b-9328-475e-af0a-18021935eb6a | Product name | 1 | 20180220 |
| 597b1cfd-7b31-5048-62be-ca5cd740da2f | Product name | 1 | 20140508 |
| ec2149b3-5c6d-5344-f757-c86411073075 | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 47593-119-16 | Oxy-Gard | 18930 mL in 1 PAIL | SOLUTION | 18930 | 5 | |
| 47593-119-17 | Oxy-Gard | 56780 mL in 1 DRUM | SOLUTION | 56780 | 5 | |
| 47593-119-21 | Oxy-Gard | 208200 mL in 1 DRUM | SOLUTION | 208200 | 5 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| DODECYLBENZENESULFONIC ACID | ACTIVE INGREDIENT | 60NSK897G9 | 2 | |
| HYDROGEN PEROXIDE | ACTIVE INGREDIENT | BBX060AN9V | 2 | |
| LACTIC ACID | ACTIVE INGREDIENT | 33X04XA5AT | 2 | |
| DODECYLBENZENESULFONIC ACID | ACTIVE MOIETY | 60NSK897G9 | 2 | |
| HYDROGEN PEROXIDE | ACTIVE MOIETY | BBX060AN9V | 2 | |
| LACTIC ACID | ACTIVE MOIETY | 33X04XA5AT | 2 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Products#
Every source-derived product name is available through these pages.
- Oxy-Gard
- Hydrogen Peroxide, Lactic Acid, Dodecyl Benzene Sulfonic Acid
- HYDROGEN PEROXIDE
- DODECYLBENZENESULFONIC ACID
- LACTIC ACID
- WATER
- GLYCERIN
- SORBITOL
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 47593-119 | 47593-119-16, 47593-119-17, 47593-119-21 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYDROGEN PEROXIDE | BBX060AN9V | ACTIB |
| DODECYLBENZENESULFONIC ACID | 60NSK897G9 | ACTIB |
| LACTIC ACID | 33X04XA5AT | ACTIB |
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| SORBITOL | 506T60A25R | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, CHEWABLE / ORAL | 3555 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | AEROSOL, FOAM / TOPICAL | 4.95 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | SUSPENSION / RECTAL | 46.18 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRA-ARTICULAR | 45 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION, SOLUTION / INTRAVENOUS | 4050 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRASYNOVIAL | 45 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION, CONCENTRATE / ORAL | 300 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CREAM / TOPICAL | 36.8 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | LIQUID / TOPICAL | 1 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CAPSULE / ORAL | 1111 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, COATED / ORAL | 12.96 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | SYRUP / ORAL | 4370 mg/5ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1.04 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | LOTION / TOPICAL | 10.7 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | SPRAY / NASAL | 49 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | GUM, CHEWING / ORAL | 6168 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, FILM COATED / ORAL | 5 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION / NASAL | 25 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SYSTEM / TOPICAL | 6300 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.